Dutch Court Sides With Teva In Spat Over MS Drug Patent

Law360, New York (October 3, 2013, 4:58 PM EDT) -- A Dutch court has rebuffed a bid by Mylan Laboratories Inc. to have Teva Pharmaceutical Industries Ltd.’s patent for its multiple sclerosis drug Copaxone declared invalid, the latter company announced Thursday.

The District Court in the Hague made the ruling in Mylan’s patent-revocation action, rejecting each of the company’s arguments that Teva’s European Patent 762,888, which covers the relapsing-remitting MS drug, is invalid, according to Teva.

The ruling follows a similar win Israel-based Teva scored in the U.K. High Court of Justice in July, which found the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.